Compare Chevron Corp (CVX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs BIO-TECHNE Corp — how do they compare? Chevron Corp trades at $196.49 (market cap $382.34B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Chevron Corp is far larger — about 34× BIO-TECHNE Corp's market cap, and Chevron Corp pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| CVX | TECH | |
|---|---|---|
Market Cap | $382.34B | $11.24B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $72.29 |
52-Week Low | $146.72 | $43.31 |
Enterprise Value | $410.88B | $11.32B |
Dividend Yield | 3.65% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chevron (CVX) trades at $186.57, down 1.42% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and a 12.25% ROE, while expanding investments in projects like Argentina's Vaca Muerta. Valuation metrics appear reasonable with a P/E of 17.96 and EV/EBITDA of 7.06.
The outlook is mixed: high oil prices and strategic investments offer growth potential, but declining revenue and net income since 2022 pose risks. Analyst consensus is bullish with a $214.25 price target, yet geopolitical tensions and operational execution challenges require monitoring. The stock presents a value opportunity with a stable dividend, though investors face volatility from energy market fluctuations.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
